REGN Sentiment Analysis

REGENERON PHARMACEUTICALS, INC. Hits QuantWave's Price Target Forecast with 16.89% Profit

Published on April 4, 2025

On January 14, 2025, QuantWave's automated forecasting platform issued a short signal for REGENERON PHARMACEUTICALS, INC....

REGENERON PHARMACEUTICALS, INC. Hits QuantWave Price Target Forecast with 17.34% Profit

Published on April 4, 2025

REGENERON PHARMACEUTICALS, INC....

JIM CRAMER ENCOURAGES INVESTORS TO OWN REGENERON PHARMACEUTICALS INC.

Published on March 16, 2025

In the latest episode of Mad Money, renowned financial expert Jim Cramer expressed his bullish stance on Regeneron Pharmaceuticals Inc. (REGN). He emphasized that the company's innovative approach to drug development and strong fundamentals make it a...

Regeneron Pharmaceuticals Inc.: A Promising Investment Opportunity

Published on March 15, 2025

Regeneron Pharmaceuticals Inc....

Regeneron Pharmaceuticals Inc. Reports Promising Results, Garnering Attention from Investors

Published on March 1, 2025

Regeneron Pharmaceuticals Inc....

Regeneron Pharmaceuticals Faces Legal Pressure and Growth Potential, According to Analysts

Published on February 26, 2025

Regeneron Pharmaceuticals, Inc. (REGN) is currently facing mounting pressure on both its sales and legal fronts....

Analyst Cuts Regeneron Pharmaceuticals REGN Price Target After Sales Concerns and Investor Lawsuit Hagens Berman

Published on February 13, 2025

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) faced a setback as an industry analyst recently cut the company's price target....

Regeneron Pharmaceuticals Inc REGN Q4 2024 Earnings Call Highlights: Strong Revenue Growth ... Yahoo Finance

Published on February 10, 2025

Regeneron Pharmaceuticals Inc....

Regeneron Pharmaceuticals Inc REGN Reports Strong Earnings in Q4 2024

Published on February 9, 2025

Regeneron Pharmaceuticals Inc....

Regeneron Pharmaceuticals Sees Positive Outlook, Analysts Say

Published on February 7, 2025

Regeneron Pharmaceuticals, Inc....

Regeneron Pharmaceuticals Inc. faces legal action for Securities Law Violations - Seek advice from The Gross Law Firm

Published on February 6, 2025

Regeneron Pharmaceuticals Inc....

Regeneron Pharmaceuticals Inc. REGN Faces Securities Class Action After Q3 2024 Earnings Report

Published on February 5, 2025

Regeneron Pharmaceuticals Inc. (REGN) is facing a securities class action lawsuit following its Q3 2024 earnings report....

Regeneron Pharmaceuticals Inc. Receives Positive Reviews from Analysts

Published on February 4, 2025

Regeneron Pharmaceuticals Inc....

Regeneron Pharmaceuticals Inc. Receives Positive Analyst Recommendations

Published on February 3, 2025

Regeneron Pharmaceuticals Inc....

Regeneron Pharmaceuticals Inc. Faces Class Action Lawsuit

Published on February 2, 2025

Regeneron Pharmaceuticals Inc. (REGN) is currently facing a class action lawsuit filed by investors....

Regeneron Pharmaceuticals Inc.: A Rising Star in the Biotech Industry

Published on January 31, 2025

Regeneron Pharmaceuticals Inc....

Regeneron Pharmaceuticals Inc. REGN: A Leader in Biopharmaceutical Innovation

Published on January 29, 2025

Regeneron Pharmaceuticals Inc....

Regeneron Pharmaceuticals Inc. REGN: A Promising Investment Amidst Falling Stocks

Published on January 28, 2025

Regeneron Pharmaceuticals Inc....

Regeneron Pharmaceuticals Inc. REGN: A Promising Investment Opportunity

Published on January 26, 2025

Regeneron Pharmaceuticals Inc....

Deadline Alert: Regeneron Pharmaceuticals Inc. REGN

Published on January 25, 2025

Regeneron Pharmaceuticals Inc....

Regeneron Pharmaceuticals, Inc. Announces Positive Results from Clinical Trial of its Breakthrough Drug

Published on January 24, 2025

Regeneron Pharmaceuticals, Inc....

Regeneron Pharmaceuticals Faces Securities Class Action After 9 Billion Value Loss

Published on January 23, 2025

Regeneron Pharmaceuticals, Inc. (REGN) is currently facing a securities class action following a significant loss in value....

Regeneron Pharmaceuticals REGN Faces Securities Class Action After Losing 9 Billion Value Following Q3 2024 Earnings Report

Published on January 22, 2025

Regeneron Pharmaceuticals Inc....

Regeneron Pharmaceuticals Faces Shareholder Class Action Lawsuit

Published on January 12, 2025

Regeneron Pharmaceuticals, Inc., a leading biotechnology company, is currently facing a shareholder class action lawsuit....

Regeneron Pharmaceuticals Inc. Poised for Strong Growth in Q4 and Full Year 2024

Published on January 10, 2025

Regeneron Pharmaceuticals, Inc....